Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Higher-dose G-CSF for poor stem cell mobilization in multiple myeloma
RBR-6bw8bwvPhase 3Recruiting
- Sponsor
- Universidade Federal de Juiz de Fora
- Start
- Jun 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of granulocyte colony-stimulating factor in multiple myeloma (MM) (2 arms), sponsored by Universidade Federal de Juiz de Fora. Primary endpoint: Achievement of CD34+ threshold by day 5. Started Jun 2024; status: recruiting.
02
Drugs
granulocyte colony-stimulating factor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on RBR-6bw8bwv.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-6bw8bwv.